Heparin-induced Thrombocytopenia (HIT)
Conditions
Keywords
Heparin-induced thrombocytopenia, HIT, heparin therapy, heparin treatments, molecular weight heparin, IgG antibodies, platelet factor 4 (PF4), heparin complex, thrombotic risk
Brief summary
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Adult patient (≥ 18 years of age) * Hospitalized at HUS between 01/01/2009 and 31/12/2019 * Specimen sent to the HUS Hematology Laboratory for biological diagnosis of HIT between 01/01/2009 and 31/12/2019 * Data collected by the CRPV and analyzed by the HIT multidisciplinary group in order to reach a consensus decision on the presence or absence of HIT * Patient does not object to the reuse of his medical data for scientific research purposes.
Exclusion criteria
* Patient for whom no test has been performed at the HUS Hematology Laboratory * Patient for whom no data has been collected by the CRPV * Patient for whom the HIT group could not confirm or deny the presence of HIT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retrospective description of the biological diagnosis approach for heparin-induced thrombocytopenia (HIT) in the Hematology laboratory of the University Hospitals of Strasbourg | through study completion, an average of 1 month |
Countries
France
Contacts
Primary ContactAgathe HERB, PharmD
Outcome results
None listed